Giampaolo Tortora

61.0k total citations · 8 hit papers
639 papers, 24.4k citations indexed

About

Giampaolo Tortora is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Giampaolo Tortora has authored 639 papers receiving a total of 24.4k indexed citations (citations by other indexed papers that have themselves been cited), including 380 papers in Oncology, 243 papers in Pulmonary and Respiratory Medicine and 196 papers in Molecular Biology. Recurrent topics in Giampaolo Tortora's work include HER2/EGFR in Cancer Research (88 papers), Cancer Genomics and Diagnostics (84 papers) and Lung Cancer Treatments and Mutations (83 papers). Giampaolo Tortora is often cited by papers focused on HER2/EGFR in Cancer Research (88 papers), Cancer Genomics and Diagnostics (84 papers) and Lung Cancer Treatments and Mutations (83 papers). Giampaolo Tortora collaborates with scholars based in Italy, United States and Spain. Giampaolo Tortora's co-authors include Fortunato Ciardiello, Roberto Bianco, Sabino De Placido, Emilio Bria, Vincenzo Damiano, A R Bianco, Gabriella Fontanini, Davide Melisi, Rosa Caputo and Angelo Raffaele Bianco and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Giampaolo Tortora

606 papers receiving 23.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Antagonists in Cancer Treatment

2008 1.6k citations Fortunato Ciardiello, Giampaolo Tortora profile →
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

2019 1.5k citations Giampaolo Tortora et al. profile →
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

2001 839 citations Fortunato Ciardiello, Giampaolo Tortora profile →
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

2000 817 citations Fortunato Ciardiello, Roberto Bianco et al. profile →
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

2001 531 citations Fortunato Ciardiello, Rosa Caputo et al. profile →
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

2015 504 citations Giampaolo Tortora et al. profile →
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

2018 391 citations Giampaolo Tortora et al. Annals of Oncology profile →
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

2015 375 citations Luisa Carbognin, Sara Pilotto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giampaolo Tortora Italy	69	13.8k	9.9k	7.8k	4.8k	2.5k	639	24.4k
Wilko Weichert Germany	73	10.1k 0.7×	8.6k 0.9×	5.8k 0.7×	5.0k 1.1×	2.9k 1.1×	516	22.1k
Jennifer R. Grandis United States	75	10.5k 0.8×	10.6k 1.1×	5.0k 0.6×	4.1k 0.9×	3.1k 1.2×	342	23.4k
David S. Hong United States	77	10.4k 0.8×	9.5k 1.0×	6.3k 0.8×	5.8k 1.2×	2.1k 0.9×	817	23.2k
Ravi Salgia United States	90	10.6k 0.8×	12.5k 1.3×	8.4k 1.1×	3.7k 0.8×	1.8k 0.7×	626	27.5k
Manuel Hidalgo United States	85	18.5k 1.3×	12.5k 1.3×	7.0k 0.9×	7.4k 1.6×	3.1k 1.2×	448	29.7k
Kenneth J. O’Byrne Australia	72	12.7k 0.9×	8.4k 0.8×	10.5k 1.3×	5.0k 1.0×	1.5k 0.6×	598	23.7k
Atsushi Ochiai Japan	82	11.2k 0.8×	8.9k 0.9×	7.8k 1.0×	4.2k 0.9×	5.2k 2.1×	594	25.1k
Masakazu Toi Japan	68	10.8k 0.8×	8.0k 0.8×	6.1k 0.8×	6.9k 1.4×	1.4k 0.6×	666	21.5k
Manfred Dietel Germany	85	10.9k 0.8×	12.3k 1.2×	5.1k 0.6×	6.2k 1.3×	3.0k 1.2×	528	26.0k
Timothy A. Chan United States	77	10.4k 0.7×	9.4k 0.9×	5.5k 0.7×	5.2k 1.1×	2.0k 0.8×	243	22.7k

Countries citing papers authored by Giampaolo Tortora

Since Specialization

Citations

This map shows the geographic impact of Giampaolo Tortora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giampaolo Tortora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giampaolo Tortora more than expected).

Fields of papers citing papers by Giampaolo Tortora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giampaolo Tortora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giampaolo Tortora. The network helps show where Giampaolo Tortora may publish in the future.

Co-authorship network of co-authors of Giampaolo Tortora

This figure shows the co-authorship network connecting the top 25 collaborators of Giampaolo Tortora. A scholar is included among the top collaborators of Giampaolo Tortora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giampaolo Tortora. Giampaolo Tortora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vita, Emanuele, et al.. (2025). Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report. The Oncologist. 30(3). 1 indexed citations

Rossi, Esther Diana, Natalia Cappoli, Antonino Mulè, et al.. (2025). Immunohistochemical expression of Ki-67, INSM1, and SSTR2A in medullary thyroid carcinoma: correlation with tumour size, vascular invasion, and biochemical outcome. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin.

Vita, Emanuele, Armando Orlandi, Gennaro Daniele, et al.. (2024). The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis. Cancer Treatment and Research Communications. 41. 100842–100842. 3 indexed citations

Rossi, Ernesto, Michela Croce, Giovanni Schinzari, et al.. (2021). Uveal Melanoma Metastasis. Cancers. 13(22). 5684–5684. 32 indexed citations

Noia, Vincenzo Di, Ettore D’Argento, Sara Pilotto, et al.. (2020). Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study. Cancer Immunology Immunotherapy. 70(6). 1583–1592. 11 indexed citations

Trestini, Ilaria, Αναστάσιος Γκουντάκος, Luisa Carbognin, et al.. (2019). Muscle derangement and alteration of the nutritional machinery in NSCLC. Critical Reviews in Oncology/Hematology. 141. 43–53. 14 indexed citations

Carbone, Carmine, Geny Piro, Vincenzo Di Noia, et al.. (2019). Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Mediators of Inflammation. 2019. 1–10. 43 indexed citations

Noia, Vincenzo Di, Ettore D’Argento, Sara Pilotto, et al.. (2018). Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. Expert Opinion on Biological Therapy. 18(9). 937–945. 12 indexed citations

Γκουντάκος, Αναστάσιος, Sara Pilotto, Andrea Mafficini, et al.. (2018). Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex. Carcinogenesis. 39(8). 971–980. 53 indexed citations

10.

Piro, Geny, Carmine Carbone, Ivana Cataldo, et al.. (2016). An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clinical Cancer Research. 22(24). 6164–6175. 68 indexed citations

11.

Carbognin, Luisa, Isabella Sperduti, Rolando Nortilli, et al.. (2015). Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials. Cancer Treatment Reviews. 41(3). 262–270. 15 indexed citations

12.

Santoni, Matteo, Alessandro Conti, Francesco Piva, et al.. (2015). Role of STAT3 pathway in genitourinary tumors. PMC. 1 indexed citations

13.

Bria, Emilio, Luisa Carbognin, Jenny Furlanetto, et al.. (2014). Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. Cancer Treatment Reviews. 40(7). 847–856. 22 indexed citations

14.

Melisi, Davide, Melissa Frizziero, Anna Tamburrino, et al.. (2014). Toll-Like Receptor 9 Agonists for Cancer Therapy. Biomedicines. 2(3). 211–228. 32 indexed citations

15.

Bria, Emilio, Giovanni De Manzoni, Stefania Beghelli, et al.. (2012). A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Annals of Oncology. 24(3). 693–701. 52 indexed citations

16.

Rosa, Roberta, Davide Melisi, Vincenzo Damiano, et al.. (2011). Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K - Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research. 17(20). 6531–6541. 44 indexed citations

17.

Damiano, Vincenzo, Sonia Garofalo, Roberta Rosa, et al.. (2009). A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action. Clinical Cancer Research. 15(22). 6921–6930. 25 indexed citations

18.

Bianco, Roberto, Roberta Rosa, Vincenzo Damiano, et al.. (2008). Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research. 14(16). 5069–5080. 117 indexed citations

19.

Melisi, Davide, Satoshi Ishiyama, Guido M. Sclabas, et al.. (2008). LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics. 7(4). 829–840. 262 indexed citations

20.

Ciardiello, Fortunato, Rosa Caputo, G Pomatico, et al.. (2000). Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. International Journal of Cancer. 85(5). 710–715. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact